Boston Scientific Corporation · NYSE:BSX

Boston Scientific — J.P. Morgan Healthcare Conference 2020

31 slides from Boston Scientific's conference presentation, January 2020

  1. Slide 1: Mike Mahoney, Chairman and Chief Executive Officer

    Mike Mahoney Chairman and Chief Executive Officer

  2. Slide 2: Safe harbor for forward-looking statements

    Safe harbor for forward-looking statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like “anticipate,” “expect,”

  3. Slide 3: Regulatory disclaimers

    Regulatory disclaimers Product Regulatory Disclaimer WATCHMAN FLX™ CE Marked. U.S.: Caution: Investigational Device. Limited by Federal (or U.S.) law to investigational use only. Not available for sale. ACURATE neo2™ Self-Expanding Valve Platform Pending CE Mark. U.S.: Caution: Investigational Devic

  4. Slide 4: Financial disclaimers

    Financial disclaimers Market Estimates: Unless noted otherwise, all references to market sizes, market share positions, and market growth rates are BSX internal estimates. Non-GAAP Financial Measures: This presentation contains non-GAAP measures (denoted with *) in talking about our company’s perfor

  5. Slide 5: Our Mission and Values

    Our Mission and Values Boston Scientific is dedicated to transforming lives through innovative medical solutions that improve the health of patients around the world. Meaningful High Global Diversity & Winning Caring Innovation Performance Collaboration Inclusion Spirit 5

  6. Slide 6: What to expect from BSX 2020+

    What to expect from BSX 2020+ 1. Highly engaged and driven team – patient-centric, motivated and innovative global culture 2. Continued execution of category leadership strategy and portfolio diversification into higher growth, adjacent markets 3. Compelling and differentiated pipeline driven by mea

  7. Slide 7: Category leadership driving growth

    Category leadership driving growth 2019 revenue1 $10.7B, 11.1% op* growth, 7.3% organic* growth Interventional Cardiology Cardiac Rhythm (incl. Structural Heart) Management $2.8B, +11%, +10% $1.9B, +1% Structural Heart Electrophysiology High end of $329M, +7% $700-725M guidance2 Peripheral Intervent

  8. Slide 8: Driving global expansion, building scale and capabilities

    Driving global expansion Building scale and capabilities Strong, balanced growth in every region Emerging Markets remain a key growth driver 2020+ LACA $0.4B, +7% +15% APAC $1.9B, +12% $1.25B, +19% 2019 US Revenue1t $6.1B, +10% EMEA $2.3B, +9% 2019 2 2020E 2021E 2022E t Excludes Spec Pharma Growth r

  9. Slide 9: Track record of delivering high performance: Organic revenue growth

    Track record of delivering high performance: Organic revenue growth Driving market share, entering new high growth segments and expanding geographic reach Est Organic* CAGR 6-9% Organic* CAGR 7% Organic* CAGR 6% Organic* CAGR (1%) 2011 2012 2013 2014 2015 2016 2017 2018 2019 1 2020E- 2022E 9

  10. Slide 10: Track record: Operating margin improvement and EPS growth

    Track record of delivering high performance: Operating margin improvement and EPS growth Delivering on adjusted operating Consistent double digit adjusted EPS* growth margin* expansion goals ’15-’19E CAGR: 14% Adj. operating margin* goal Adj. EPS* growth goal +DD% Y/Y +50-100 $1.55- $1.58 26- bps Y/

  11. Slide 11: Consistent portfolio diversification into higher growth markets

    Consistent portfolio diversification into higher growth markets BSX portfolio revenue mix High growth markets (≥8% CAGR): IC (Structural Heart), RM (EP), PI (Drug Eluting, Venous, $11B ~35% Therapeutic Oncology), NM, Endo (TIPs, Endoluminal Surgery), UroPH (Prostate Health) $8B ~25% $7B ~15% ~10% Mo

  12. Slide 12: Multiple sources of innovation drive compelling pipeline

    Multiple sources of innovation drive compelling pipeline Internal adjusted R&D* % of Disciplined and balanced Strategic investments & revenue at the high end of peers approach to M&A partnerships ~10.5% • Tuck-ins across multiple • Active venture capital portfolio 10.5-11% businesses 10.8% – 40+ inv

  13. Slide 13: Large and compelling high growth markets across the portfolio

    Large and compelling high growth markets across the portfolio 2019 BSX Sales1 Mkt Growth Key Products / New Markets Operational* Growth 2019 – 2022 CAGR • LAAC Global Expansion (WATCHMAN™) Interventional $2.8B • TAVR (ACURATE neo™, LOTUS Edge™) +6% Cardiology +11% and Embolic Protection (Sentinel™)

  14. Slide 14: Strong product pipeline supports top tier growth

    Strong product pipeline supports top tier growth 2020E 2021E 2022E+ Coronary Therapies Coronary Therapies Coronary Therapies • SYNERGY XD, 48 mm, MEGATRON – U.S. • AVVIGO Guidance System • NG Atherectomy System • SYNERGY XD – Japan • ROTAWIRE Drive - US and Japan • SYNERGY XD – China • Comet II pres

  15. Slide 15: Key portfolio growth drivers 2020+

    Key portfolio growth drivers 2020+ Selected product spotlights Structural BTG Single-use Heart Venous & Scopes Interventional Oncology 15

  16. Slide 16: Structural Heart: differentiated portfolio in $6B market

    1) Structural Heart Differentiated portfolio stands out in $6B market BSX Structural Heart revenue $900M to $1B in 2020E WATCHMAN™ LAAC SENTINEL™ Cerebral Prevent Protection System WATCHMAN FLX US H2:20E Stroke PROTECTED TAVR CHAMPION AF trial (H2H DOAC) launch 2020E trial launch H1:20E Match Aortic

  17. Slide 17: WATCHMAN: Expanding clinical investments: CHAMPION-AF

    WATCHMAN Expanding clinical investments: CHAMPION-AF Estimated Global Estimated Global LAAC Market Size LAAC Market Size CHAMPION-AF Study  A randomized, controlled trial studying WATCHMAN FLX vs. DOACs  Lower bleeding risk patients with non-vascular atrial fibrillation 2025E+ (NVAF) 2023E $2B+ 20

  18. Slide 18: BTG: Venous & Interventional Oncology

    2) BTG: Venous & Interventional Oncology Strong strategic fit, high growth adjacencies Significant operational & Access to BTG IM high growth adjacencies commercial synergies Interventional Oncology Venous Disease • Engaging customers as a newly 2018 Market: $1.6B 2018 Market: $1.4B combined entity

  19. Slide 19: Single-use endoscopes: $2B+ market opportunity

    3) Single-use endoscopes: $2B+ market opportunity Reduce infection, enhance efficiency, and improve availability EXALT MODEL D COMPREHENSIVE SINGLE-USE THERAPEUTIC IMAGING PORTFOLIO Exalt™ Model D Exalt™ Model B Duodenoscope Bronchoscope 1.5M ERCPs 3M procedures SpyGlass™ Discover Exalt™ Model Bx Ch

  20. Slide 20: Strong cash flow generation outlook

    Strong cash flow generation outlook Capital structure facilitates Compelling adj. free cash flow*: 10% CAGR 2019E-2022E growth strategy • Closed $4B BTG acquisition +10% ~$2.8B August 2019 ~$2.5B ~$2.3B • Expect to repay $1.6B debt ~$2.1B over 16 months post-BTG close • Targeting BBB+ credit ratings

  21. Slide 21: Consistent top tier financial performance & outlook

    Consistent top tier financial performance & outlook Goals 2019E 2020E-2022E Organic Revenue* +7.3%1 +6-9% CAGR Operational Revenue* +11.1%1 TBD Adj. Operating Margin* +50-75bps3 Y/Y +50-100 bps Improvement annually Adj. Tax Rate* ~9%3 ~11%7 Less ~100bps stock comp benefit Adj. EPS* Growth 11%-13% Do

  22. Slide 22: Ongoing commitment to Corporate Social Responsibility

    Ongoing commitment to Corporate Social Responsibility PEOPLE PLANET PRACTICES Ranked 47% 87 greenhouse 28th gas emissionst Product launches 10/20/40 30% 95% of solid Progress on water waste diverted $1B+ D&I goals consumptiont Invested in R&D from landfillst 114 99.9% Active Clinical 55 Awareness &

  23. Slide 23: References and Non-GAAP Disclosures

    gBostong, , er clientl References and Non-GAAP Disclosures Advancing science for life™

  24. Slide 24: Acronym Reference Guide

    Acronym Reference Guide Afib Atrial Fibrillation IO Interventional Oncology BPH Benign Prostatic Hyperplasia MIT Minimally Invasive Techniques CRM Cardiac Rhythm Management NM Neuromodulation DBS Deep Brain Stimulation NVAF Non-valvular Atrial Fibrillation DCB Drug Coated Balloon PCI Percutaneous Co

  25. Slide 25: References

    References *Non-GAAP measure; for reconciliations of non-GAAP financial measures to the most directly comparable GAAP figures, please refer to Appendix A of this document. 1Based on preliminary, unaudited sales results issued January 14, 2020 2Based on preliminary, unaudited internal estimates 3Base

  26. Slide 26: Supplemental Non-GAAP Disclosures

    Supplemental Non-GAAP Disclosures Less: Impact of Less: Impact Foreign of Recent FY 2019 Divisional Revenue Growth 1 (unaudited) compared to FY Currency Operational Acquisitions / Organic 2018 Reported Basis Fluctuations Basis Divestitures Basis Endoscopy 8% -2% 9% 0% 9% Urology & Pelvic Health 13%

  27. Slide 27: Supplemental Non-GAAP Disclosures

    Supplemental Non-GAAP Disclosures Less: Impact of Foreign FY 2019 Regional Revenue Growth 1 (unaudited ) compared to FY Currency Operational 2018 Reported Basis Fluctuations Basis U.S. 10% 0% 10% EMEA (Europe, Middle East and Africa) 4% -5% 9% APAC (Asia-Pacific) 10% -2% 12% LACA (Latin America and

  28. Slide 28: Supplemental Non-GAAP Disclosures

    Supplemental Non-GAAP Disclosures Revenue Growth 2019 1 2018 2017 2016 2015 2014 2013 2012 2011 Revenue growth, as reported 9% 9% 8% 12% 1% 3% -1% -5% -2% Less: Impact of foreign currency fluctuations -2% 1% 0% 0% -7% -3% -2% -2% 3% Operational Revenue Growth 11% 8% 8% 12% 8% 6% 1% -3% -5% Less: Imp

  29. Slide 29: Supplemental Non-GAAP Disclosures

    Supplemental Non-GAAP Disclosures Earnings Per Diluted Share 2019E3,5 2018 4 2017 2016 2015 2014 2013 2012 2011 2010 GAAP net income (loss) per share $0.72 - $0.75 $ 1.19 $ 0.08 $ 0.25 $ (0.18) $ (0.09) $ (0.09) $ (2.89) $ 0.29 $ (0.70) Non-GAAP adjustments 0.83 0.28 1.18 0.86 1.11 (a) 0.93 (b) 0.82

  30. Slide 30: Supplemental Non-GAAP Disclosures

    Supplemental Non-GAAP Disclosures Adjusted Free Cash Flow ( in billions) 2019E3 2018 2017 2016 Operating cash flow, reported $ 0.3 $ 1.4 $ 1.2 Less: Purchases of property, plant and equipment 0.3 0.3 0.4 Add: Proceed on disposals of property, plant and equipment - - - Free Cash Flow, as reported $ -

  31. Slide 31: Supplemental Non-GAAP Disclosures

    Supplemental Non-GAAP Disclosures The following is an explanation of the adjustments that management excluded from GAAP measures to calculate the following forward-looking non-GAAP financial measures: Adjusted Gross Margin: Excludes from GAAP gross margin the impacts of forecasted acquisition- and d

Boston Scientific — J.P. Morgan Healthcare Conference 2020 on 6ix